Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CCR5Delta32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response.

AIDS (London, England) - 23 Nov 2001

Brumme Z L, Chan K J, Dong W, Hogg R, O'Shaughnessy M V, Montaner J S, Harrigan P R

Abstract excerpt

OBJECTIVE: Natural genetic polymorphisms within the CCR5 gene and promoter have been linked to patterns of HIV-1 clinical disease progression in untreated individuals. The objective of this retrospective study was to assess the influence of the CCR5Delta32 mutation and promoter polymorphisms on virological and immunological treatment outcome in 436 antiretroviral-naive individuals initiating their first therapy,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiretroviral Therapy, Highly Active
Share to CD4 Lymphocyte Count

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD4-Positive T-Lymphocytes

Share to HIV Infections

Share to Linkage Disequilibrium

Share to Patient Compliance

Share to Receptors, CCR5

Share to Viral Load

Source

Identifiers

PMID: 11698699
DOI: 10.1097/00002030-200111230-00007

Genes

CCR5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CCR5Delta32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response.PMID 11698699Read ↗

Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.Semantic proximity Read ↗

Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy.Semantic proximity Read ↗

Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.Semantic proximity Read ↗

CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection.Semantic proximity Read ↗

CCR5 genotype and pre-treatment CD4+ T-cell count influence immunological recovery of HIV-positive patients during antiretroviral therapy.Semantic proximity Read ↗

Frequency of a mutated CCR-5 allele (delta32) among Italian healthy donors and individuals at risk of parenteral HIV infection.Semantic proximity Read ↗

Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?Semantic proximity Read ↗

Role of CCR5, CCR2 and SDF-1 gene polymorphisms in a population of HIV-1 infected individuals.Semantic proximity Read ↗

HIV-1 Infection in Persons Homozygous for CCR5-Δ32 Allele: The Next Case and the Review.Semantic proximity Read ↗

Association of heterozygous CCR5Δ32 deletion with survival in HIV-infection: A cohort study.Semantic proximity Read ↗

CCR5 Promoter Polymorphism −2459G > A: Forgotten or Ignored?Semantic proximity Read ↗

CCR5-del32 is not deleterious in the homozygous state in humansSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.